A5329: Interferon –Free Therapy for Chronic Hepatitis C Virus Genotype 1 infection in persons with HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy: A5334s Pharmacokinetic Substudy
Study Location:
Baltimore
Topic:
Hepatitis and HIV
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT02194998?term=a5329&rank=1
IRB#:
Pro00010596
Coordinator:
Anna Wimpelberg (Washington)
Ilene Wiggins, RN (Baltimore)
Enrollment:
Closed
Trial Period:
Ongoing
A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C medications. New “direct acting antiviral” drugs (DAAs) ABT-450/r/ABT-267 plus ABT-333 will be tested as part of a drug regimen that does not contain the drug interferon for either 24 or 12 weeks of treatment.
- HIV and Hepatitis C co-infected people 18 to 70 years old
- HIV viral load less than 50 copies
- Currently on one of the following HIV regimens:
- raltegravir or darunavir/ritonavir AND tenofovir plus FTC or 3TC
- No history of resistance or failure of anti-HIV therapy
- CD4 count greater than 200
- No prior HCV treatment
- HCV viral load greater than 10,000
- HCV genotype 1
Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org
Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu